CIK 0000748592 · Non-accelerated filer<br>Smaller reporting company
Ernexa Therapeutics Inc.
Sign in to watch- Ticker
- ERNA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 311103425
- Phone
- (617) 798-6700
- Business address
- 1035 CAMBRIDGE STREET, SUITE 18A, CAMBRIDGE, MA, 02141
- Former names
- Eterna Therapeutics Inc., Brooklyn ImmunoTherapeutics, Inc., NTN BUZZTIME INC, NTN COMMUNICATIONS INC
Securities
- ERNA Common Stock Nasdaq
- ERNAW Warrants Nasdaq
- 3 Insider Initial Statement of Ownership
- SC 13D/A Stake Beneficial Ownership Report
- 4 Open-market buy Interim CEO bought 3,458,629 shares at $0.20 ($691,726)
- 4 Gift Director gave 100,000 shares (gift)
- 4 Gift Interim CEO gave 100,000 shares (gift)
- 10-Q Report Quarterly Report
- 8-K Event Results of operations
- 4 Open-market buy INTERIM CEO bought 10,000 shares at $0.19 ($1,908)
- 4 Open-market buy INTERIM CEO bought 1,500 shares at $0.20 ($305)
- SC 13D/A Stake Beneficial Ownership Report
- 4 Open-market buy INTERIM CEO bought 52,000 shares at an average $0.19 ($9,878)
- 4 Open-market buy INTERIM CEO bought 1,110,684 shares at $0.17 ($188,816)
- 4 Open-market buy INTERIM CEO bought 18,431 shares at an average $0.17 ($3,048)
- 4 Open-market buy EVP and Chief Product Officer bought 4,200 shares at $0.22 ($924)
- 10-Q Report Quarterly Report
- 8-K Event Results of operations
- 4 Grant or award EVP/Chief Product Officer acquired 250,000 shares (grant or award)
- 4 Grant or award Chief Information Officer acquired 60,000 shares (grant or award)
- 4 Grant or award Chief Financial Officer acquired 150,000 shares (grant or award)
- 4 Derivatives Options or other derivatives
Page 46 of 77 · 1,525 filings